Category: Side Effect: Cardiovascular (heart attack, stroke, heart failure, PE, DVT)
-
Fibromyalgia Drug Savella Should Be Pulled From Market, Says Public Citizen Group
January 2010 Petition Letter To FDA Is Sent One Year After The Medication Was Approved For Sale In U.S. (Posted by Tom Lamb at DrugInjuryWatch.com) On January 21, 2010 the Health Research Group arm…
-
Should Meridia Remain On Market? FDA Says “Yes” (For Now At Least), European Drug Regulators Say “No”
Difference Of Opinion Suggests There Could Be A Possible Meridia Recall In U.S. Before The FDA Holds Its Public Advisory Meeting In September 2010(Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: Abbott Pulls Meridia in U.S. Amid…
-
Safety “Cloud” Gets Removed From Spiriva By FDA In January 2010
This COPD Medication Had Previously Been Possibly Linked To Stroke, Heart Attack, And Death (Posted by Tom Lamb at DrugInjuryWatch.com) On January 14, 2010 the FDA issued a news release, "FDA Updates Earlier Guidance…
-
Medical Journal Report: Adverse Drug Reactions And Pulmonary Embolism Are Often Difficult For Doctors To Diagnose
These Commonly Missed Diagnoses Are Particularly Relevant To Women Using YAZ, Yasmin, And Ocella, As Well As NuvaRing And Ortho Evra (Posted by Tom Lamb at DrugInjuryWatch.com) The November 9, 2009 issue of the…
-
Diet Drug Meridia Has Possible Cardiovascular Risks, Including Stroke, Heart Attack, And Cardiac Death
FDA Early Communication About Meridia (Sibutramine) Side Effects Issued by Agency In November 2009 (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________________ UPDATE: Abbott Pulls Meridia in U.S. Amid FDA Safety Concerns (10/8/10, Bloomberg) Abbott…
-
November 2009 Medical Journal Article Describes Large Ongoing Study About Safety Of YAZ
INAS-OC Study: Intended To Evaluate Risk Of Developing Cardiovascular Side Effects For Women Who Use YAZ (DRSP/EE 24d) (Posted by Tom Lamb at DrugInjuryWatch.com) In May 2009 we first wrote about the International Active…
-
Anemia Drugs Procrit And Aranesp May Increase Twofold The Risk Of Potentially Fatal Blood Clots
Results From Large Long-Term Study Show Association Between These Erythropoiesis-Stimulating Agents And Venous Thromboembolism (Posted by Tom Lamb at DrugInjuryWatch.com) In late October 2009 we learned that the results from the Trial to Reduce Cardiovascular…
-
Aranesp Associated With Increased Risk For Stroke In Patients With Diabetes And Chronic Kidney Disease
TREAT Study Revealed, Also, That This Amgen Anemia Drug Was No Better Than Placebo In Reducing Deaths Or Cardiovascular Problems (Posted by Tom Lamb at DrugInjuryWatch.com) The anemia drug Aranesp (darbepoetin alfa) might cause an increased…
-
Yasmin And Yaz Birth Control Pills Are Under Scrutiny By Drug Regulators In Europe
Bayer Confirms To German Newspaper There Are 129 Yasmin / Yaz Lawsuits In U.S. As Of Mid-October 2009 (Posted by Tom Lamb at DrugInjuryWatch.com) From an October 21, 2009 article, "Bayer under pressure as…
-
Waiting For The Results From Swissmedic Safety Analysis Of Yaz And Other Drospirenone-Containing Contraceptives
Prompted By Investigation Into Death Of Young Woman Who Died While Using Yaz; Results Of Analysis Expected In Late October 2009 (Posted by Tom Lamb at DrugInjuryWatch.com) In late September 2009 we learned that…